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Background: Childhood obesity and early puberty are intermediate risk factors for later metabolic and reproductive
disorders including diabetes, polycystic ovarian syndrome (PCOS), and breast cancer. Atypical methylation patterns
in genes related to hormone and adipose metabolism, such as CYP19A1 (aromatase) and PPARG (peroxisome
proliferator-activated receptor gamma), are associated with alterations in gene expression which may contribute to
pathogenesis of these diseases. If present in early life, it is conceivable similar methylation aberrations may result
in hormone perturbations that alter pubertal timing.
Methods: We used Cox proportional hazard models to investigate whether promoter methylation of CYP19A1 and
PPARG, independently or in concert with body weight, was associated with age at breast (B2) or pubic hair
development (PH2) when assayed in saliva DNA collected from a cohort of New York City, Black and Hispanic girls
(N = 130) enrolled in a study of pubertal timing between 6–8 years of age.
Results: An inverse association between CYP19A1 methylation and risk of early PH2 was suggested (HR = 0.95, 95%
CI = 0.90-1.00, p = 0.05). CYP19A1 methylation also appeared to modify risk of early B2 associated with body weight.
Specifically, compared to normal weight girls with ‘high’ CYP19A1 methylation, significantly increased risk of early
B2 was observed in overweight girls with ‘low’ but not ‘high’ CYP19A1 methylation (HR = 2.15; 95% CI = 1.23- 3.76).
However, in formal tests for effect modification, the interaction between body weight and methylation did not
reach statistical significance (p for interaction = 0.085). PPARG methylation was not significantly associated with
PH2 or B2.
Conclusions: Though limited by sample size, our findings suggest methylation of CYP19A1, a critical gene in
estrogen biosynthesis, may influence timing of breast development in overweight girls. Consistent with emerging
reports, these data support the notion that epigenetic marks in surrogate tissues may improve risk prediction when
added to standard plasma and anthropometric indicators, and warrant further study.
Keywords: Aromatase, Methylation, Obesity, PPAR, PubertyBackground
Emerging evidence indicates modifiable lifestyle factors
and time-stable epigenetic determinants influence child-
hood obesity [1,2] and timing of puberty [3]. Childhood
obesity and early puberty are risk factors for several
metabolic and reproductive disorders, including: early
menarche [4], adult obesity [5], diabetes [6], polycystic* Correspondence: jia.chen@mssm.edu
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reproduction in any medium, provided the orovarian syndrome (PCOS) [7], and breast cancer [8].
PCOS and its common childhood antecedent, premature
pubarche, are associated with hyperinsulinemia and an-
drogen excess in overweight females [7,9]. Similarly, plasma
leptin [10] and local adiposal estrogen [11] are associated
with breast tumor growth in obese postmenopausal cases,
and are hypothesized to drive early breast development and
menarche in overweight girls [12-15]. Given that the ovaries
are largely quiescent pre-menarche and post-menopause, it
is conceivable biomarkers that link adiposity to pubertal
timing may inform risk of androgen and estrogen-relatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ploratory pilot study we asked whether promoter methyla-
tion marks in PPARG or CYP19A1, two genes that connect
energy balance to lifetime estrogen exposure, are associated
with pubertal development in girls.
The transcription factor PPARγ is a master regulator
of adipose differentiation and endocrine function. Human
and animal data link PPARG hypermethylation to reduced
PPARγ expression that is observed in cases of diabetes
[16], breast cancer [17], and hyperandrogenic PCOS [9].
Because PCOS and early pubarche share hyperinsulemia
and androgen excess as common clinical features, it is
conceivable PPARG methylation aberrations may alter
timing of pubarche if present in early development [9].
Aromatase (product of the CYP19A1 gene) catalyzes
all bodily estrogen biosynthesis via aromatization of
androgen precursors, and inhibitors of this enzyme are
highly effective therapies for estrogen-sensitive cancers
of the breast [18]. Aromatase expression varies across
tissues and individuals owing to differential activation
and repression of several tissue-specific gene promoters.
Each of these promoters regulates a unique untranslated
‘first exon’ (‘exons I’) that is spliced to the common cod-
ing exons II-X and can be mapped back to its promoters
for purposes of deducing what factors drive transcription
in a particular tissue [19]. In healthy adipose, CYP19A1
is expressed in fibroblasts primarily from activation of a
distal glucocorticoid-regulated promoter termed ‘pI.4’,
and is lost in the path of adipocyte differentiation driven
by PPARγ [20]. In malignant breast biopsies, CYP19A1 is
overexpressed 3–4 fold in tumor and proximal adipose
tissue from several tissue-specific promoters [21], but pri-
marily from two largely ‘gonad-specific’ cAMP-responsive
promoters termed “pII/I.3” [22] that are activated by can-
cer-associated transcription factors PPARγ suppresses in
healthy breast [17,23]. Though this phenomenon of in-
creased tissue-specific promoter usage with preference for
gonadal promoters (termed ‘promoter switching’) is well-
documented in the breast cancer literature [19,24], its
timing and extent of tissue distribution related to inter-
mediate risk indicators is less understood. Demura and
Bulun [25] recently described hypomethylation of a
CpG dinucleotide in the ‘cAMP-response element-like
sequence’ (CLS) of pII/I.3, which they detected in aroma-
tase-overexpressing fibroblasts derived from a skin-punch
biopsy of a healthy patient. In light of the aggregate of
findings regarding CYP19A1 misexpression from gonadal
promoters in breast cancer cases, Demura and Bulun pos-
tulated CYP19A1 pII/I.3 hypomethyaltion may contribute
to the phenomenon of ‘promoter switching’ and inter-
individual variability in lifetime estrogen exposure.
In the present study we sought to determine whether
methylation of this CYP19A1 pII/I.3 locus [25] or the
average of five CpG dinucleotides in a differentiallymethylated region of the PPARG promoter [9,16,26] was
associated with timing of pubic hair (PH2) or breast
development (B2) in a cohort of New York City, Black
and Hispanic girls who were enrolled in a study of




Prospective cohort study and part of the Puberty Studies
of the Breast Cancer and Environment Research Program
(BCERP) [27]. The overarching goal of this longitudinal
investigation is to identify genetic and environmental risk
factors related to altered timing of puberty onset in girls.
Girls, 6 to 8 years of age, from East Harlem schools, com-
munity health centers, and the Mount Sinai Pediatric
clinic were recruited for this study between 2004–2007, as
previously reported [28]. Consent was obtained from
parents or guardians and child assent was independently
verified; the study was approved by the Institution Review
Board at Mount Sinai. Eligibility included age, female sex,
no underlying endocrine medical conditions, and self-
identified Black or Hispanic race/ethnicity. A total of 416
girls were enrolled in the study at baseline; we restricted
our analysis to the 130 who had whole saliva collected.
The distribution of major demographic and physiological
variables, including race, caregiver’s education, BMI,
breast stage and pubic stage, showed no significant differ-
ence between those who donated saliva samples and those
who did not (data not shown).
Demographic and anthropometric data collection
Uniformly trained interviewers conducted annual in-
person interviews and standardized anthropometric
measurements. Annual pubertal stage assessments
were performed by physicians or nurse practitioners
according to BCERP consortium-standardized protocols;
the principal endpoints were age at first pubic hair and
breast development as described in detail previously [27].
A structured questionnaire was administered to the girl’s
parent or guardian in either English or Spanish. Informa-
tion ascertained through the questionnaire included med-
ical history and demographic variables. Body mass index
(BMI) was calculated as weight (in kg) divided by height
(in cm)-squared. We classified girls as ‘overweight’ accord-
ing to Centers for Disease Control (CDC) and Prevention
criteria, where overweight girls had a BMI at or above the
85th percentile of their age and sex-specific BMI distribu-
tion. Age at B2 was defined as the midpoint between the
age at the last visit where the girl was staged B1 with no
prior staging greater than B1 and the age at the first visit
where the girl was staged B2 with no subsequent staging
less than B2. Girls who entered the study at B2 were
assigned age at B2 as six months prior, and girls with a
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sored. Age at PH2 was assigned in the same manner.
Saliva DNA collection and processing
Interviewers instructed study participants to deposit saliva
in pre-barcoded 2 ml Oragene DNA Self-Collection Kit
tubes (DNA Genotek, Canada; REF OG-100) according to
the manufacturer’s instructions. Barcoded vials were logged
in our database by scanning upon receipt in the laboratory.
DNA was extracted from whole saliva collected in Oragene
tubes (DNA Genotek) with the ITprep kit (DNA Genotek)
according to the manufacturer’s instructions.
Methylation assessment by pyrosequencing
Genomic DNA was bisulfite-converted with the Epitect
DNA kit (Qiagen, Carslbad, CA). Pyrosequencing was
performed on CYP19A1 and PPARG PCR products ampli-
fied from bisulfite-treated DNA with the Pyromark PCR
kit (Qiagen) and the primers listed in Additional file 1.
Cycling conditions were 95°C for 15 minutes followed by:
45 cycles of 94°C for 30 seconds; annealing temperature
for 30 seconds; 72°C for 30 seconds; with a final extension
step of 72°C for 10 minutes. PCR products were sequen-
ced using the Pyromark Q24 system and kit (Qiagen). Per-
cent methylation for each region of interest was quantified
using Pyromark Q24 software version 1.0.1 (Qiagen). Gen-
omic coordinates for the promoter regions amplified are
included in Additional file 1; coordinates were obtained
from the UCSC Genome Browser (http://genome.ucsc.
edu), human assembly: February 2009, GRCh37/hg19).
Laboratory personnel performing DNA methylation ana-
lysis were blinded to subject information.
Statistical analysis
We examined relationships among methylation and study
characteristics with parametric (t-tests) and non-para-
metric (Mann-Whitey U tests) statistics and multivariate
linear regression. Cox proportional hazard models were
used to identify associations between DNA methylation
and age at PH2 or B2. Interaction was examined by
including a group variable that was constructed by pairing
the dichotomized methylation (below vs. greater than or
equal to their medians) and dichotomized body size (nor-
mal weight vs. overweight). All models were adjusted for
Hispanic ethnicity, Black race, and caregiver education
level. All analyses were performed using SAS (version
9.1.3 for PC; SAS Institute Inc., Cary, NC).
Results
Study population demographics according to CYP19A1
and PPARG methylation
Study subjects (N = 130) were Black or Hispanic girls
living in the East Harlem neighborhood of New York
City. Girls were recruited in local clinics and communitycenters between 2004–2007, and were 6 (72 months) to
8.9 (107 months) years old with a mean age of 7.5 years
(89.5 months) at time of enrollment. Based on CDC
criteria, 39.2% of our study subjects were considered over-
weight (≥ 85th percentile of their age and sex-specific BMI
distribution) and 25.4% were considered obese (≥ 95th per-
centile). Of the study subjects’ primary caregivers, 59%
had completed high school. Among the 130 whole saliva
samples collected, 5 failed the pyrosequencing assay for
CYP19A1 and 1 for PPARG, leaving 125 and 129 samples,
respectively, with methylation data. CYP19A1 methylation
values ranged from 77% to 95% (mean: 88.8% ± 3.5% SD).
PPARG methylation ranged from 5.6% to 19% (mean:
10.4% ± 2.1% SD). Associations between methylation levels
and key demographic variables are summarized in Table 1.
No significant differences were observed with respect
to race, ethnicity, BMI percentile, or caregiver’s edu-
cation level.
Gene methylation related to milestones of pubertal
development
We investigated whether methylation of CYP19A1 or
PPARG was related to age at B2 or PH2 using Cox
Proportion Hazards Models (Table 2). For PH2, we ob-
served an inverse association with CYP19A1 methylation
in unadjusted models; for a one percent increase in
CYP19A1 methylation, girls were 5% more likely to be
older at PH2 (HR = 0.95; 95% CI = 0.90-0.99). This asso-
ciation was attenuated in models adjusted for ethnicity,
BMI percentile, and caregiver’s education (HR = 0.95,
95% CI = 0.90-1.00). Conversely, no significant associa-
tions between age at B2 and CYP19A1 methylation were
observed. In addition, no significant associations among
PPARG methylation and PH2 or B2 were observed.
Effect of body size modified by gene methylation
Obesity is one of the strongest predictors of pubertal on-
set [29]. Therefore we next sought to determine whether
gene methylation modifies the relationship between BMI
and age at PH2 and B2. We created ‘normal weight’ and
‘overweight’ categories of body size (below and greater
than or equal to the 85th percentile for age and sex-
specific BMI distribution), and ‘high’ and ‘low’ methyla-
tion (above and below the median). As shown in Table 3,
compared to normal weight girls with high CYP19A1
methylation (low risk referent), risk of earlier breast
development was greater among overweight girls with low
CYP19A1 methylation (HR = 2.15, 95% CI = 1.23 - 3.76).
This BMI-methylation interaction reached borderline
significance in formal tests for effect modification (p for
interaction = 0.085). A similar effect was observed for
CYP19A1 methylation and age at PH2, although the inter-
action did not reach statistical significance (p for inter-
action = 0.21). Lastly, no significant interactions between
Table 1 Study population demographics according to CYP19A1 and PPARG methylation (%)
CYP19A1 methylation (%) PPARG methylation (%)
Characteristic N Mean (SD) p N Mean (SD) p
Overall 125 88.84 (3.45) - 129 10.45 (2.14) -
Child ethnicity
Hispanic* 100 89.06 (3.39) 0.75** 102 10.51 (2.18) 0.28**
Not hispanic 25 87.96 (3.59) 27 10.21 (2.00)
Child race
Black* 44 88.48 (3.39) 0.39 45 10.45 (2.36) 0.98
Not black 81 89.03 (3.48) 84 10.44 (2.02)
Caregiver education
≤High school 75 89.12 (3.58) 0.34 78 10.37 (2.17) 0.93
>High school 45 88.49 (3.31) 46 10.40 (2.14)
Baseline BMI
<85th 76 88.80 (3.53) 0.88 79 10.47 (2.06) 0.86
≥85th 49 88.89 (3.37) 50 10.4 (2.28)
*includes 19 individuals who are self- identified as Black Hispanics.
**p for the nonparametric Mann Whitney U test.
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were detected.
Discussion
Early breast and pubic hair development have been associ-
ated with disordered leptin, insulin, and IGF-1 profiles in
overweight girls in numerous studies [30]. Perturbations
in estrogens and androgens, critical drivers of breast and
pubic hair development, remain clinically more chal-
lenging to detect [31]. Given national trends, there is
great motivation to identify biomarkers that add value
to current plasma and anthropometric measures used
in predicting puberty onset [32]. In this exploratory
study we aimed to ascertain whether salivary methylation
of the CYP19A1 and PPARG promoters was related to age
at breast or pubic hair development in girls, both inde-
pendently and in concert with body size. In light of the
current literature, we anticipated overweight girls with
CYP19A1 hypomethylation and PPARG hypermethylation
might be predisposed to early breast development [33-35],Table 2 Associations between CYP19A1 and PPARG methylati
Unadjusted model
N HR (95% CI) p va
Pubic Hair (PH2) development
CYP19A1 125 0.95 (0.90 - 0.99) 0.0
PPARG 129 0.99 (0.90 - 1.08) 0.7
Breast development (B2)
CYP19A1 125 0.97 (0.92 - 1.02) 0.1
PPARG 129 1.04 (0.96 - 1.13) 0.3
*Cox proportional hazard models were adjusted for child race/ethnicity, BMI percen
5 subjects. 95% CI = 95% confidence interval.and those with PPARG hypermethylation to early pubic
hair development [9,16].
Our main observations were that relative hypomethyla-
tion of a CpG in the gonadal CYP19A1 promoter termed
“pII “ was associated with earlier age at B2 among over-
weight girls only (Table 3), and with earlier age at PH2 in-
dependent of body size (Table 2). While only correlative
and based on a relatively small number of samples, our B2
findings are supported by a case report authored by
Demura and Bulun [25], which describes hypomethylation
of pI.3/II in CYP19A1-overexpressing fibroblasts relative
to CYP19A1-quiescent fibroblasts derived from punch
biopsies of four healthy subjects. In their report, CYP19A1
activity was robustly induced in the former upon cAMP
stimulation, while fibroblasts from the other three subjects
were cAMP-refractory. Further investigation revealed
CpG dinuleotides within and proximal to the CLS (CRE-
like sequence) of gonadal pI.3/II were relatively hypo-
methylated in cAMP-responsive CYP19A1-overexpressing
fibroblasts, and were relatively hypermethylated in non-on (%) and age at pubertal development.
Adjusted model*
lue N HR (95% CI) p value
4 120 0.95 (0.90 - 1.00) 0.05
5 124 0.96 (0.87 - 1.05) 0.37
7 120 0.96 (0.91 - 1.01) 0.11
2 124 1.03 (0.94 - 1.12) 0.54
tile, and caregiver education. Education information was missing from
Table 3 Interaction of body size and relative gene
methylation in predicting age at pubertal development
Pubic hair (PH2) Breast (B2)
N HR (95% CI) N HR (95% CI)
CYP19A1 (N = 120)
Normal weight,
high methylation
37 1.00 (referent) 37 (referent)
Normal weight,
low methylation
39 1.04 (0.63, 1.7) 39 0.82 (0.50, 1.33)
Overweight,
high methylation
25 1.05 (0.61, 1.81) 25 1.32 (0.78, 2.23)
Overweight,
low methylation
24 1.80 (1.04, 3.12) 24 2.15 (1.23, 3.76)
p for interaction 0.21 0.085
PPARG (N = 124)
Normal weight,
low methylation
35 1.00 (referent) 35 1.00 (referent)
Normal weight,
high methylation
44 1.10 (0.65, 1.85) 44 1.33 (0.81, 2.18)
Overweight,
low methylation
29 1.42 (0.83, 2.42) 29 1.84 (1.08, 3.13)
Overweight,
high methylation
21 1.21 (0.67, 2.18) 21 1.94 (1.08, 3.49)
p for interaction 0.52 0.55
Overweight was defined as BMI at or above the 85th percentile for age. ‘Low’
and ‘high’ methylation were defined as below or above the median level of %
methylation for each gene locus (89% for CYP19A1, 10.4% for PPARG). Models were
adjusted for child race/ethnicity, and caregiver education (< vs. ≥ high school).
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that CYP19A1 hypomethylation may be an early ‘permis-
sive’ event, which renders one susceptible to subsequent
intrinsic/extrinsic transcriptional activators of CYP19A1,
and concomitant local or systemic estrogen excess. Such a
‘two-hit’ mechanism of derepression (hypomethylation)
and activation (e.g., obesity-related cytokines) may also
explain why CYP19A1 hypomethylation was associated
with early B2 in overweight, but not normal weight girls in
the present study.
Aromatase catalyzes estrogen biosynthesis from andro-
gen precursors. Elevated androgen, insulin, and IGF-1
signaling are widely accepted co-determinants of early
pubarche in overweight girls [7,30,36]. Thus, our finding
that CYP19A1 hypomethylation (theoretical increase in
expression) was related to earlier age at PH2, independent
of BMI (Table 2), was unanticipated. While intriguing, the
statistical significance of this association was attenuated
after adjustment for covariates, and we can only speculate
as to its implications without further study.
We assessed methylation of the −383 to −281 bp region
of the PPARG promoter as PPARγ suppresses CYP19A1
expression in breast tissues in culture [20,33], and relative
hypermethylation of this region has been associated with
reduced PPARγ expression in hyperandrogenic PCOS [9]and diabetes models [16]. Though we detected no statisti-
cally significant effects related to PPARG methylation in
the present study, puberty-associated methylation patterns
may exist in genes for PPARγ co-factors, effectors, or
downstream targets in salivary or other surrogate tissue
DNA. Indeed, methylation biomarkers of childhood adi-
posity and maternal BMI have been described in RXRA
and PPARGC1A when assayed in umbilical tissue [2,37].
This exploratory investigation has several limitations
regarding generalizability, including but not limited to:
small sample size, lack of perceived stress assessments,
use of candidate genes, and DNA derived from whole sal-
iva samples collected only from Black and Hispanic girls.
We describe salivary CYP19A1 hypomethylation not as a
‘causal’ event, but merely as a ‘surrogate biomarker’ that
with further study may have utility in predicting risk of
premature breast development in overweight girls. Spe-
cifically, the CpG we describe is contained in a critical
transcription factor binding site (CLS), located in a strong
CYP19A1 gonadal promoter termed ‘pII’, which is acti-
vated by the ubiquitous pleiotropic second messenger
cAMP in the follicular phase of the menstrual cycle [38].
DNA methylation is highly tissue-specific, and CYP19A1
is not likely expressed in buccal epithelial cells from
gonadal pII to any significant degree. However, weighing
these considerations together supports the notion that hy-
pomethylation of CYP19A1 pII in whole saliva- a tissue in
which expression from gonadal pII is likely silenced, may
in fact represent a methylation aberration, possibly
established early in life. Such a mark could be deemed a
‘surrogate’ aberration if it portends risk generalizable to
more functional tissues with niche transcriptional machin-
ery requisite to affect CYP19A1 expression changes that
promote disease, as has been extensively reported for pII
and estrogen-related disorders [22,24].
Our findings are only suggestive and only extend to
saliva samples we collected from Black and Hispanic girls.
Procurement of effector/target tissues (e.g. adipose/breast)
to investigate the validity of salivary pII methylation as a
risk surrogate in a statistically robust manner in more
diverse pediatric populations is precluded by ethical, logis-
tical, and economic considerations. However, animal and
cell line co-culture models designed to capture adipose
and developing breast tissue interactions are emerging
[39,40], and it will be interesting to follow developments
that functionally characterize the complex biological and
environmental interactions that orchestrate epigenetic
factors related to thelarche and pubarche onset.
Conclusions
Consistent with emerging human and animal studies, our
findings suggest methylation of CYP19A1 may influence
timing of breast development in overweight girls. These
data warrant further investigation, and support the notion
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current plasma and anthropometric measures used in pre-
dicting timing of puberty onset.
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